Dr. Yvonne Angell has more than twenty years experience in the field of peptide therapeutics. She has initiated, led and advanced research teams and programs at Eli Lilly, Pfizer, Affymax, Ipsen, ChemPartner, GenEdit, and is currently Executive Director of TIDES Discovery Project Management at STA Pharmaceuticals, a WuXi Apptec company. Her primary expertise lies in design, synthesis, lead optimization and early development of therapeutic peptides, oligonucleotides, proteins and conjugates. In addition, she has designed and optimized novel polymers to enable non-viral, non-lipid nanoparticle delivery for tissue targeting of genetic therapies. She has experience in a wide range of therapeutic areas including hematology, oncology, neurology and endocrinology. She has advanced many drug discovery programs including ten drug candidates into preclinical development, one to the market and one in phase 2 clinical trials.

She is active in her field and currently serves as President of the Boulder Peptide Foundation and founder of TIDEtalks. She also plays an active role on the advisory boards for several prominent conferences in the peptide and oligo therapeutic fields. She received her PhD from the University of Wisconsin, Madison, and carried out postdoctoral research as an NIH fellow at the University of Minnesota, Minneapolis. She is an inventor on many patents and has numerous scientific publications.